Zevra Therapeutics Sells SDX Portfolio for $50 Million

By Chris Stiles • Monday, March 16 11:33 • Permanent Link

Zevra Therapeutics, Inc. has announced the sale of its entire SDX portfolio, including Azstarys® and KP1077, to Commave Therapeutics SA for $50 million. This agreement comes after a 2019 license agreement where Zevra granted Commave an exclusive license to certain SDX products. The sale also marks the resolution of a 2024 litigation in Delaware Chancery Court initiated by Commave against Zevra.

As part of the agreement, Zevra has repaid the principal balance on its $63 million term loan in full, resulting in a debt-free balance sheet. This move has significantly enhanced the company's financial and strategic flexibility.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick Disease Type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Today the company's shares have moved -1.0% to a price of $8.93. For the full picture, make sure to review ZEVRA THERAPEUTICS, INC.'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.